🇺🇸 FDA
Pipeline program

PRAX-222 - Initial Dose

PRAX-222-111

Phase 2 small_molecule active

Quick answer

PRAX-222 - Initial Dose for SCN2A-DEE is a Phase 2 program (small_molecule) at PRECISION BIOSCIENCES INC with 1 ClinicalTrials.gov record(s).

Program details

Company
PRECISION BIOSCIENCES INC
Indication
SCN2A-DEE
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials